[High-dose progestational contraception: side effects].

Contraception, fertilite, sexualite · 1993 · vol. 21(2) , pp. 129–31 · PMID:12318011 · W2259031351
article OA: closed CC0
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-06, 2026-06-13

High-dose progestational contraception, used mainly when estrogens are contraindicated, can cause menstrual disorders, weight gain, and atherogenic metabolic changes, though nor-pregnane derivatives may not negatively impact lipid and glucide parameters.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Progestational contraception (CMP) is rarely used. In France, its indications are not clearly defined. The prescription is justified when there is a contra-indication to estrogen use (uterus fibroids, endometrial hyperplasia, endometriosis, fibro-cystic disease of the breast). The side effects are menstruation disorders (metrorrhagias, amenorrhea), weight gain, atherogenic metabolic changes. Actually, nor-pregnane derivatives, which correctly block ovulation, do not seem to have a deleterious effect on glucide and lipid parameters. At last, it is not sure that CMP may be prescribed to a patient previously treated for a breast cancer.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Contraceptives, Oral Contraception Contraceptive Agents Contraceptive Agents, Female Developed Countries Europe Family Planning Services France

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:39.448046+00:00
License: CC0 · commercial use OK